Space food

DGAP-News: BLACKHAWK CEO FREDERICK PELS AND MINDBIO THERAPEUTICS CO-FOUNDER JUSTIN HANKA WILL LEAD INVESTOR PRESENTATION AND Q&A SESSION WEDNESDAY, FEBRUARY 2nd AT 3PM PACIFIC STANDARD TIME

Retrieved on: 
Tuesday, February 1, 2022

BLACKHAWK CEO FREDERICK PELS AND MINDBIO THERAPEUTICS CO-FOUNDER JUSTIN HANKA WILL LEAD INVESTOR PRESENTATION AND Q&A SESSION WEDNESDAY, FEBRUARY 2nd AT 3PM PACIFIC STANDARD TIME

Key Points: 
  • BLACKHAWK CEO FREDERICK PELS AND MINDBIO THERAPEUTICS CO-FOUNDER JUSTIN HANKA WILL LEAD INVESTOR PRESENTATION AND Q&A SESSION WEDNESDAY, FEBRUARY 2nd AT 3PM PACIFIC STANDARD TIME
    The issuer is solely responsible for the content of this announcement.
  • Vancouver, British Columbia - February 1, 2022 - Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the "Company" or "Blackhawk") is pleased to announce that its CEO Frederick Pels, along with MindBio Therapeutics co-founder, Justin Hanka, will conduct an investor presentation and question and answer session on Wednesday, Feburary 2nd at 3pm PST.
  • Details of the investor presentation are as follows:
    The presentation will be recorded and published on the MindBio https://mindbiotherapeutics.com and Blackhawk website on conclusion of the presentation.
  • Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies.

DGAP-News: BLACKHAWK GROWTH'S MINDBIO THERAPEUTICS ADVANCES MICRODOSING CLINICAL TRIAL TO 59 PATIENTS

Retrieved on: 
Monday, November 15, 2021

Vancouver, British Columbia - November 15, 2021 - Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the "Corporation" or "Blackhawk"), is pleased to announce that their wholly-owned subsidiary, MindBio Therapeutics Pty Ltd ("MindBio"), has reached a new milestone for its Phase 1 clinical trial microdosing LSD with 59 participants successfully completing the trial.

Key Points: 
  • Vancouver, British Columbia - November 15, 2021 - Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the "Corporation" or "Blackhawk"), is pleased to announce that their wholly-owned subsidiary, MindBio Therapeutics Pty Ltd ("MindBio"), has reached a new milestone for its Phase 1 clinical trial microdosing LSD with 59 participants successfully completing the trial.
  • The clinical trial is the first and largest safety clinical trial of its kind anywhere in the world.
  • MindBio is on track to have its Phase 1 clinical trial in 80 healthy participants completed by April in 2022.
  • Clinical trial participants are assessed on a comprehensive range of psychometric and biometric markers to determine safety and efficacy of the drug.

DGAP-News: BLACKHAWK GROWTH'S MINDBIO THERAPEUTICS LOOKS TO EXPAND MICRODOSING CLINICAL TRIALS

Retrieved on: 
Monday, November 1, 2021

Vancouver, British Columbia - November 01, 2021 - Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the "Corporation" or "Blackhawk"), is pleased to announce that MindBio Therapeutics Pty Ltd ("MindBio") is working to expand its microdosing clinical trials.

Key Points: 
  • Vancouver, British Columbia - November 01, 2021 - Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the "Corporation" or "Blackhawk"), is pleased to announce that MindBio Therapeutics Pty Ltd ("MindBio") is working to expand its microdosing clinical trials.
  • In its phase 1 clinical trial microdosing LSD (Lysergic Acid Diethylamide), MindBio is microdosing LSD to 80 healthy participants who take the drug at home in the same way that they would take any other medication.
  • MindBio will lead phase 2 clinical trials microdosing LSD to patients with major depressive disorder and in patients with late-stage cancer - with those trials set to begin in mid-2022.
  • MindBio is currently assessing natural psilocybin and potential analogs as a candidate for phase 1 microdosing clinical trials.

DGAP-News: BLACKHAWK GROWTH'S MINDBIO THERAPEUTICS SUCESSFULLY PROGRESSED TO THE SECOND HALF OF THEIR PHASE 1 MICRODOSING CLINICAL TRIAL

Retrieved on: 
Monday, October 4, 2021

The progress in clinical trials makes MindBio a step closer towards commercialization and bringing new therapies to market.

Key Points: 
  • The progress in clinical trials makes MindBio a step closer towards commercialization and bringing new therapies to market.
  • The clinical trials have been approved by the New Zealand Government who also contributed NZ$600,000 in funding to support this important safety study.
  • Furthermore, the Government of New Zealand has provided an import license and approval for the substances to be administered at home.
  • It is the first clinic trial of its kind in the world that tests microdosing of 80 participants with psychedelics in a community setting.

DGAP-News: GAIA GROW PROVIDES UPDATE ON TRU EXTRACTS R&D LICENSE APPLICATION AND PRODUCT DEVELOPMENT

Retrieved on: 
Thursday, September 23, 2021

The licensing process is considered an amendment to the existing licenses in place and should be approved within a few weeks.

Key Points: 
  • The licensing process is considered an amendment to the existing licenses in place and should be approved within a few weeks.
  • These applications are for TRU's own products as well as for sub-tenants Leaf and Mark and Spaced Food.
  • Gaia Grow is an Alberta-based vertically-integrated licensed hemp company with subsidiaries licensed for cannabis and hemp processing, extraction, product formulation, novel product development and cannabis retail.
  • Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties.

DGAP-News: BLACKHAWK GROWTHS MINDBIO THERAPETUICS PLANS TO COMMERVIALIZE INTELLECTUAL PROPERTY GENERATED FROM UNIVERSITY OF AUCKLAND CLINICAL TRIAL IN PSYCHEDELIC THERAPY IN ADVANCED STAGE CANCER PATIENTS

Retrieved on: 
Thursday, September 16, 2021

MindBio Theraepeutics plans to commercialize the intellectual property generated from the University of Auckland clinical trial in psychedelic assisted therapy in advanced-stage cancer patients.

Key Points: 
  • MindBio Theraepeutics plans to commercialize the intellectual property generated from the University of Auckland clinical trial in psychedelic assisted therapy in advanced-stage cancer patients.
  • The administration of high-dose psychedelic compounds has shown clinically significant benefits in the treatment of psychological distress in advanced cancer patients.
  • This study will evaluate the feasibility of conducting a randomised controlled trial comparing psychedelic-microdose assisted in people who have advanced cancer, anxiety or depression.
  • The findings will inform the development of a larger trial and provide initial indication of potential benefits of psychedelic microdosing in advanced cancer.

DGAP-News: BLACKHAWK GROWTH'S MINDBIO THERAPEUTICS OPENS WORLD CLASS FACILITY FOR THE PHARMACEUTICAL INDUSTRY

Retrieved on: 
Monday, September 13, 2021

MindBio Therapeutics is excited to announce that it will open a world class facility providing research and drug development as a service to the pharmaceutical industry to potential clients in the United States and Canada.

Key Points: 
  • MindBio Therapeutics is excited to announce that it will open a world class facility providing research and drug development as a service to the pharmaceutical industry to potential clients in the United States and Canada.
  • Companies in the psychedelic and pharmaceutical industry can now contract with MindBio Therapeutics for research and drug development on any psychedelic compound.
  • Large pharmaceutical companies are increasingly looking to create synthetics compounds of psychedelics and MindBio Therapeutics has the ideal platform and access to infrastructure to help accelerate this activity.
  • With its exclusive agreement with the University of Auckland, MindBio has access to expansive infrastructure to bring psychedelic medicines to market.

DGAP-News: BLACKHAWK GROWTH SUBSIDIARY, MINDBIO THERAPEUTICS, ACCELERATES PHASE 1 & PHASE 2 MICRODOSING CLINICAL TRIALS

Retrieved on: 
Tuesday, September 7, 2021

Within the next 6 months, MindBio Therapeutics will complete the remainder of phase 1 trials microdosing LSD.

Key Points: 
  • Within the next 6 months, MindBio Therapeutics will complete the remainder of phase 1 trials microdosing LSD.
  • - Phase 2 Clinical Trials have also just been approved with microdosing of LSD in late-stage cancer patients.
  • - MindBio Therapeutics has also three phase 2 clinical trials in planning where microdoses of LSD will be tested against depression, chronic pain and mild cognitive impairment.
  • A recent peer review has shown that MindBio Therapeutics is one of very few publicly reported psychedelic companies involved in both Phase 1 and Phase 2 clinical trials.

Developing innovative food production technologies with the Deep Space Food Challenge

Retrieved on: 
Tuesday, January 12, 2021

LONGUEUIL, QC, Jan. 12, 2021 /CNW Telbec/ - Today, the Canadian Space Agency (CSA) announced the Deep Space Food Challenge in Canada, a competition to develop innovative ways of producing food for astronauts on space missions to the Moon and Mars, while expanding opportunities for food production on Earth.

Key Points: 
  • LONGUEUIL, QC, Jan. 12, 2021 /CNW Telbec/ - Today, the Canadian Space Agency (CSA) announced the Deep Space Food Challenge in Canada, a competition to develop innovative ways of producing food for astronauts on space missions to the Moon and Mars, while expanding opportunities for food production on Earth.
  • The CSA and the Privy Council Office's Impact Canada Initiative are working with NASA on the Deep Space Food Challenge.
  • The Deep Space Food Challenge is in line with Canada's Space Strategy 'scommitment to harness space to solve everyday challenges on Earth like access to nutritious food.
  • "With the Deep Space Food Challenge, we are asking Canadians to find innovative ways to produce food in deep space that could also help those living in remote regions with harsh environments, such as Canada's northern communities.